Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LLY crawled date : 2021 - 07 - 16 save search
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Published: 2021-07-16 (Crawled : 19:11) - fda.gov
REGN | $893.67 -0.04% 230K
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.07 -1.42% 800K
|
Health Technology
| Email alert
Add to watchlist
CLVS | $0.0812 -3.94%
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
| Email alert
Add to watchlist
KPTI | $1.255 -1.95% 620K
|
Health Technology
| Email alert
Add to watchlist
ADCT | $4.72 -0.84% 190K
|
Health Technology
| Email alert
Add to watchlist
YMAB | $14.77 -1.53% 320K
|
Health Technology
| Email alert
Add to watchlist
BPMC | News | $86.18 -3.06% 510K
|
Health Technology
| Email alert
Add to watchlist
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.89 1.22% 5.1M
|
Health Technology
| Email alert
Add to watchlist
AVEO | $15.0 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
LLY | $727.48 -2.48% 2M
|
Health Technology
| Email alert
Add to watchlist
cancer approval
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Published: 2021-07-16 (Crawled : 14:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
new drug baricitinib treatment dermatitis drug atopic dermatitis
Spotlight on David McAvoy, General Counsel & Chief Compliance Officer
Published: 2021-07-16 (Crawled : 13:00) - brickellbio.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
BBI | $2.12 16.04%
|
Health Technology
|
| O: -0.45%
H: 1.3%
C: -2.6%
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-16 (Crawled : 01:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
phase 1 antibody phase 2
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.